New first-line treatment combinations for chronic lymphocytic leukemia (CLL)
Paradigm Shift in the Management of Patients with Previously Untreated Chronic Lymphocytic Leukemia through NCI-sponsored Clinical Trials
This work compares different drug combinations—including ibrutinib, venetoclax, and obinutuzumab—for people with previously untreated CLL, with trials for both younger and older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11164692 on NIH RePORTER |
What this research studies
This effort follows people with newly diagnosed, untreated CLL who receive one of two frontline drug combinations to see which works better for different patients. One trial focuses on older adults (age 65 and up) while another enrolls younger patients, and participants are randomly assigned to treatment arms. Doctors will track clinical outcomes and collect blood and biomarker samples to learn who benefits most and why. Results will be used to write reports and to design the next national frontline treatment protocol.
Who could benefit from this research
Good fit: Ideal candidates are people with newly diagnosed, previously untreated CLL, with some trial arms specifically enrolling adults aged 65 and older and others open to younger adults per protocol.
Not a fit: People with relapsed or refractory CLL, other types of leukemia, or who are medically ineligible for the trial treatments would likely not benefit directly from these specific trials.
Why it matters
Potential benefit: If successful, this could identify frontline drug combinations that produce deeper and longer remissions for people with untreated CLL.
How similar studies have performed: Targeted drugs such as ibrutinib, venetoclax, and obinutuzumab have already improved outcomes in CLL, but large randomized comparisons of these exact combinations are still being completed.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Parikh, Sameer Ashok — Mayo Clinic Rochester
- Study coordinator: Parikh, Sameer Ashok
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.